Drug intelligence / Profile preview

Elpida-04

Development stage: Preclinical
Lead developer: Elpida Therapeutics
Modality: Gene Therapies

Overview

Elpida-04 is an investigational gene therapy being developed by Elpida Therapeutics for the treatment of telomere syndrome. It is currently in preclinical development. The specific modality and mechanism of action have not been publicly disclosed, but it is part of a pipeline that includes advanced therapies for rare genetic disorders, often utilizing gene therapy platforms[4][7]. The drug targets telomere syndrome, a group of disorders caused by defects in genes involved in maintaining telomere length, which can lead to premature cellular aging and organ dysfunction.

Beyond the preview

Go deeper on Elpida-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elpida-04.

Explore the full profile